Unlock instant, AI-driven research and patent intelligence for your innovation.

Pyrimido thiazole type compounds with anti-inflammatory effect and application thereof in preparation of anti-inflammatory medicaments

A compound, thiazole technology, used in anti-inflammatory agents, organic chemistry, drug combinations, etc.

Inactive Publication Date: 2013-06-12
WENZHOU MEDICAL UNIV +1
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there is no theory that can correctly predict the structure-activity relationship of whether these compounds can be anti-inflammatory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimido thiazole type compounds with anti-inflammatory effect and application thereof in preparation of anti-inflammatory medicaments
  • Pyrimido thiazole type compounds with anti-inflammatory effect and application thereof in preparation of anti-inflammatory medicaments
  • Pyrimido thiazole type compounds with anti-inflammatory effect and application thereof in preparation of anti-inflammatory medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The synthesis of embodiment 1 compound

[0035] The preparation of intermediate 12-mercapto-4-methyl-6-phenyl-1,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester: in a 250ml round bottom flask with electromagnetic stirring, add 5.3g of benzaldehyde (0.05mol), 7.8g (0.06mol) of ethyl acetoacetate, 5.7g (00.75mol) of thiourea, 3.75g (0.04mol) of sulfamic acid, 50ml of absolute ethanol, heated to reflux for 2h, cooled, filtered, washed with water, After drying, 11.7 g of intermediate 1 was obtained, with a yield of 85%.

[0036] Preparation of the compound: In a 100ml round bottom flask with a reflux condenser and drying tube, add 0.552 g of ethyl 2-mercapto-4-methyl-6-phenyl-1,6-dihydro-pyrimidine-5-carboxylate g (0.002mol), ethyl chloroacetate 0.244g (0.002mol), pyridine 0.18g (0.002mol), absolute ethanol 10ml, reflux for 4h, then add aromatic aldehyde or heterocyclic aldehyde 0.002mol, piperidine or morpholine 0.17 g (0.002mol), continue to reflux for 4h, cool the reac...

Embodiment 2

[0044] Inhibition of the compound of Example 2 on the release of inflammatory factors from macrophages stimulated by LPS

[0045] The preliminary anti-inflammatory activity of the compound in vitro was tested by using the compound to inhibit the release of inflammatory factors (TNF-α and IL-6) from RAW264.7 macrophages stimulated by LPS. The specific method is as follows: 1.2×10 6 RAW264.7 macrophages were cultured with DMEM medium at 37°C. After 24 hours, the medium was renewed, and the test compound (final concentration: 10 μM) was added for pretreatment for 2 hours, and then treated with 0.5 μg / mL LPS for 22 hours. hours, collect the culture fluid and use ELISA method to detect the content of TNF-α and IL-6; collect the cells to detect the total protein concentration, the ELISA results are divided by the corresponding total protein concentration, and the TNF-α and IL-6 in the LPS control group The content was calibrated to 100; each compound was tested three times, and the ...

Embodiment 3

[0046] Example 3 The dose-effect relationship of the active compound inhibiting the release of inflammatory factors from macrophages stimulated by LPS

[0047] The dose-effect relationship of active compounds inhibiting the release of TNF-α and IL-6 from RAW264.7 macrophages stimulated by LPS was further tested. The method was the same as in Example 2. For experimental data, see image 3 . The inhibitory activities of the compounds on TNF-α and IL-6 all have a good dose-effect relationship, among which compound H19 shows a good dose relationship, and its inhibitory rate IC50 on IL-6 and TNF-α reached 0.83 μM respectively and 4.17μM, but compound H23 had no significant dose-dependent relationship.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides pyrimido thiazole type compounds as well as a medicament composition and an anti-inflammatory application thereof.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, in particular, the invention relates to pyrimidothiazole compounds with anti-inflammatory effects. In addition, the present invention also relates to the pharmaceutical composition and anti-inflammatory application of these compounds. Background technique [0002] As an important pathological process, inflammation is very common in the human body, and it itself is an autoimmune response of the body to external or foreign body stimuli. And when this response is dysregulated or excessively responds to the body's self-injury, it evolves into inflammation. Therefore, most diseases are accompanied by the mediation and occurrence of inflammation, and the mediation and occurrence of inflammation aggravate the damage to the body of the disease, such as rheumatoid arthritis, diabetes complications, cancer, atherosclerosis, inflammatory Enteropathy etc. In these processes, proinflammatory factors such...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D513/04A61K31/519A61K31/5377A61P29/00A61P19/02A61P37/02A61P3/00
Inventor 梁广胡杰刘志国张亚利赵承光
Owner WENZHOU MEDICAL UNIV